CA2788326A1 - Compounds for use in the treatment of diseases - Google Patents

Compounds for use in the treatment of diseases Download PDF

Info

Publication number
CA2788326A1
CA2788326A1 CA2788326A CA2788326A CA2788326A1 CA 2788326 A1 CA2788326 A1 CA 2788326A1 CA 2788326 A CA2788326 A CA 2788326A CA 2788326 A CA2788326 A CA 2788326A CA 2788326 A1 CA2788326 A1 CA 2788326A1
Authority
CA
Canada
Prior art keywords
diseases
phenylaminoethane
hydrazide
epo
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2788326A
Other languages
English (en)
French (fr)
Inventor
Andreas Kubin
Paul Furtmuller
Gerhard Wolber
Daniela Schuster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INOXIA LIFESCIENCES GmbH
Original Assignee
INOXIA LIFESCIENCES GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INOXIA LIFESCIENCES GmbH filed Critical INOXIA LIFESCIENCES GmbH
Publication of CA2788326A1 publication Critical patent/CA2788326A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2788326A 2010-01-29 2011-01-28 Compounds for use in the treatment of diseases Abandoned CA2788326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA122/2010 2010-01-29
AT0012210A AT509045B1 (de) 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale
PCT/AT2011/000050 WO2011091461A1 (de) 2010-01-29 2011-01-28 Verbindungen zur verwendung bei der behandlung von erkrankungen

Publications (1)

Publication Number Publication Date
CA2788326A1 true CA2788326A1 (en) 2011-08-04

Family

ID=43707937

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2788326A Abandoned CA2788326A1 (en) 2010-01-29 2011-01-28 Compounds for use in the treatment of diseases

Country Status (12)

Country Link
US (1) US20130065962A1 (enExample)
EP (2) EP2965755A1 (enExample)
JP (1) JP5788907B2 (enExample)
KR (1) KR20120128644A (enExample)
CN (2) CN102858329B (enExample)
AT (1) AT509045B1 (enExample)
AU (1) AU2011208939B2 (enExample)
BR (1) BR112012018772A2 (enExample)
CA (1) CA2788326A1 (enExample)
MX (1) MX2012008815A (enExample)
SG (1) SG182786A1 (enExample)
WO (1) WO2011091461A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022923A1 (en) * 2012-08-10 2014-02-13 Mcmaster University Antibacterial inhibitors
WO2014138906A1 (en) * 2013-03-15 2014-09-18 Prometic Biosciences Inc. Substituted aromatic compounds and related method for the treatment of fibrosis
JP2017530182A (ja) * 2014-10-10 2017-10-12 プロメティック・ファーマ・エスエムティ・リミテッドＰｒｏｍｅｔｉｃ Ｐｈａｒｍａ Ｓｍｔ Ｌｉｍｉｔｅｄ 糖尿病の予防及び治療用の置換芳香族化合物及び医薬組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323428A1 (en) * 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082846A (en) 1976-11-18 1978-04-04 University Of Utah Method for treating psoriasis
JPH02753A (ja) * 1987-12-24 1990-01-05 Ono Pharmaceut Co Ltd カルバゾイル誘導体、それらの製造方法およびそれらを有効成分として含有するメイラード反応阻害剤
EP0323590A3 (en) 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl derivatives
EP0581904B1 (en) 1991-04-01 1997-05-28 Duke University Method of inhibiting fibrosis
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
CA2324426A1 (en) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions and methods for the treatment of cystic fibrosis
JP2002524505A (ja) * 1998-09-15 2002-08-06 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 高血中脂質濃度に因る疾患の予防または治療のための、ケイ皮酸誘導体を含む組成物
AU2004242565A1 (en) * 1999-01-12 2005-01-27 Kenneth Blum Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
AU758207B2 (en) 1999-05-28 2003-03-20 Cj Cheiljedang Corporation Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
IT1313567B1 (it) * 1999-07-27 2002-09-09 Zambon Spa Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
US6444829B1 (en) 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
KR20040105853A (ko) 2002-04-08 2004-12-16 토렌트 파마슈티칼스 리미티드 티아졸리딘-4-카르보니트릴 및 유사체와디펩티딜-펩티다아제 억제제로서의 용도
US7741352B2 (en) 2003-03-11 2010-06-22 Neurosearch A/S KCNQ channel modulating compounds and their pharmaceutical use
JP4805909B2 (ja) 2004-03-03 2011-11-02 スミスクライン ビーチャム コーポレーション 選択的アンドロゲン受容体モジュレーターとしてのアニリン誘導体
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
CN1686297A (zh) * 2005-04-07 2005-10-26 甘肃圣达医药科技有限责任公司 一种止咳平喘药物及其制备方法
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
WO2007026215A1 (en) 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
US7956064B2 (en) * 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
NZ579892A (en) 2007-03-30 2012-03-30 Sanofi Aventis Pyrimidine hydrazide compounds as prostaglandin D synthase inhibitors
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
WO2010127440A1 (en) * 2009-05-04 2010-11-11 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical uses thereof

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022923A1 (en) * 2012-08-10 2014-02-13 Mcmaster University Antibacterial inhibitors
WO2014138906A1 (en) * 2013-03-15 2014-09-18 Prometic Biosciences Inc. Substituted aromatic compounds and related method for the treatment of fibrosis
JP2016512202A (ja) * 2013-03-15 2016-04-25 プロメティック・バイオサイエンシーズ・インコーポレイテッドＰｒｏＭｅｔｉｃ ＢｉｏＳｃｉｅｎｃｅｓ Ｉｎｃ． 線維症を治療するための置換芳香族化合物及び関連方法
KR20160051676A (ko) * 2013-03-15 2016-05-11 프로메틱 파마 에스엠티 리미티드 섬유증의 치료를 위한 치환된 방향족 화합물 및 관련 방법
AU2014231648B2 (en) * 2013-03-15 2018-02-08 Liminal Biosciences Limited Substituted aromatic compounds and related method for the treatment of fibrosis
US10023518B2 (en) 2013-03-15 2018-07-17 Prometic Pharma Smt Limited Substituted aromatic compounds and related method for the treatment of fibrosis
EA030651B1 (ru) * 2013-03-15 2018-09-28 Прометик Фарма Смт Лимитед Замещенные ароматические соединения и связанный с ними способ лечения фиброза
US10550066B2 (en) 2013-03-15 2020-02-04 Prometic Pharma Smt Limited Substituted aromatic compounds and related method for the treatment of fibrosis
KR102196721B1 (ko) 2013-03-15 2020-12-30 리미널 바이오사이언시스 리미티드 섬유증의 치료를 위한 치환된 방향족 화합물 및 관련 방법
US11524930B2 (en) 2013-03-15 2022-12-13 Liminal Biosciences Limited Substituted aromatic compounds and related method for the treatment of fibrosis
JP2017530182A (ja) * 2014-10-10 2017-10-12 プロメティック・ファーマ・エスエムティ・リミテッドＰｒｏｍｅｔｉｃ Ｐｈａｒｍａ Ｓｍｔ Ｌｉｍｉｔｅｄ 糖尿病の予防及び治療用の置換芳香族化合物及び医薬組成物

Also Published As

Publication number Publication date
AU2011208939A1 (en) 2012-08-30
EP2528595A1 (de) 2012-12-05
EP2528595B1 (de) 2015-08-05
AT509045A4 (de) 2011-06-15
CN102858329B (zh) 2015-06-17
BR112012018772A2 (pt) 2016-04-12
JP5788907B2 (ja) 2015-10-07
CN102858329A (zh) 2013-01-02
AT509045B1 (de) 2011-06-15
AU2011208939B2 (en) 2015-07-09
MX2012008815A (es) 2012-11-23
CN104958286B (zh) 2018-01-05
KR20120128644A (ko) 2012-11-27
EP2965755A1 (de) 2016-01-13
SG182786A1 (en) 2012-09-27
WO2011091461A1 (de) 2011-08-04
US20130065962A1 (en) 2013-03-14
JP2013518061A (ja) 2013-05-20
CN104958286A (zh) 2015-10-07

Similar Documents

Publication Publication Date Title
US20220001014A1 (en) Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
CN101505790A (zh) 眼病的治疗
CN102462837B (zh) 抗炎组合物
Yuan et al. Artesunate protects pancreatic β-cells from streptozotocin-induced diabetes via inhibition of the NLRP3/caspase-1/GSDMD pathway
KR20150135339A (ko) 레보세티리진 및 몬테루카스트의 외상성 손상의 치료 용도
CA2788326A1 (en) Compounds for use in the treatment of diseases
KR20150138848A (ko) 레보세티리진 및 몬테루카스트의 과민증 치료 용도
Yu et al. Allergy in pathogenesis of eustachian tube dysfunction
JP2021533078A (ja) 新規のグルタミニルシクラーゼ阻害剤及び様々な疾患の治療におけるそれらの使用
CN111093661B (zh) 戊二酰亚胺衍生物用于治疗与细胞因子的异常活性相关的疾病的用途
JP6415545B2 (ja) 抑うつ障害の治療用及び／又は予防用の新規薬剤
US20250302797A1 (en) Combination therapies for treating inflammation
CA3053059C (en) Compounds for use in the prevention and/or treatment of non-alcoholic fat liver disease and non-alcoholic steatohepatitis
JP2021510157A (ja) 内皮細胞機能障害を調節するためのｒｐｓ２ペプチドの使用
EP3131545A2 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
HK1250916A1 (zh) Aerd/哮喘中的血栓烷受体拮抗剂
US20230355726A1 (en) Fibrinolytic enzyme composition for fibrosis treatment
HK40028225B (zh) 戊二酰亚胺衍生物用於治疗与细胞因子的异常活性相关的疾病的用途
OA19594A (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
CN101014369A (zh) 利用cox—2选择性抑制剂和ltb4受体拮抗剂的组合用于治疗炎症和疼痛的组合物
He et al. Mild Hypothermia Alleviates Post-Resuscitation Cerebral Injury in Rats via Modulating the Balance of the Renin–Angiotensin System
Ford et al. Novel role of dual oxidase 2 as a mediator of podocyte injury in the diabetic environment
WO2019135363A1 (ja) 腱滑膜病変を主体とした疾患の治療薬
EA043907B1 (ru) Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
JP2018514585A (ja) 腎疾患を有する患者の腎臓及び／又は心臓機能の改善方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160113

FZDE Discontinued

Effective date: 20180810